Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA’s adverse event reporting system

Expert Opinion on Drug Safety

Volumn 15, Issue 8, 2016, Pages 1003-1011

  Raisch, Dennis W ^a   Rafi, John A ^a   Chen, Cheng ^a   Bennett, Charles L ^b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

biological drugs; data mining signal detection; FDA s adverse event reporting system; Progressive multifocal leukoencephalopathy; targeted cancer therapies

Indexed keywords

ALEMTUZUMAB; BELIMUMAB; BIOLOGICAL FACTOR; BRENTUXIMAB; ECULIZUMAB; GOLIMUMAB; IBRUTINIB; IDELALISIB; MONOCLONAL ANTIBODY; NATALIZUMAB; OBINUTUZUMAB; OFATUMUMAB; RITUXIMAB; TOSITUMOMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT;

ADVERSE DRUG REACTION; ARTICLE; CD4+ T LYMPHOCYTE; CEREBROSPINAL FLUID; DRUG APPROVAL; DRUG SURVEILLANCE PROGRAM; HUMAN; MOLECULARLY TARGETED THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SIGNAL DETECTION; TREATMENT DURATION; ADULT; AGED; CHEMICALLY INDUCED; FEMALE; FOOD AND DRUG ADMINISTRATION; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MIDDLE AGED; NEOPLASMS; UNITED STATES; VERY ELDERLY;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84975318326     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1080/14740338.2016.1198775     Document Type: Article

References (53)

1. K.E.Astrom, E.L.Mancall, E.P.RichardsonJr. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin’s disease. Brain J Neurol. 1958;81(1):93–111.
2. K.R.Carson, A.M.Evens, E.A.Richey, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients:a report of 57 cases from the research on adverse drug events and reports project. Blood. 2009;113(20):4834–4840.
3. J.L.Casado, I.Corral, J.García, et al. Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era. Eur J Clin Microbiol Infect Dis. 2014;33(2):179–187.• Summarizes current epidemiology and survival from PML among HIV patients
4. K.L.Amend, B.Turnbull, N.Foskett, et al. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology. 2010;75(15):1326–1332.
5. J.R.Berger, K.Khalili The pathogenesis of progressive multifocal leukoencephalopathy. Discov Med. 2011;12(67):495–503.• Provides details regarding the mechanism of pathogenesis of PML
6. F.Zaheer, J.R.Berger. Treatment-related progressive multifocal leukoencephalopathy:current understanding and future steps. Ther Adv Drug Saf. 2012;3(5):227–239.•• Summarizes the treatments and mechanisms associated with PML associated with drug therapy
7. FDA. MedWatch:the FDA safety information and adverse event reporting program. 2016 [cited 2016 Jan15]. Available from:http://www.fda.gov/Safety/MedWatch/
8. A.Bate, S.J.Evans. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427–436.
9. T.Brewer, G.A.Colditz. Postmarketing surveillance and adverse drug reactions:current perspectives and future needs. JAMA. 1999;3;281(9):824–829.
10. J.A.Clark, S.L.Klincewicz, P.E.Stang. Spontaneous adverse event signaling methods:classification and use with health care treatment products. Epidemiol Rev. 2001;23(2):191–210.
11. M.Hauben, D.Madigan, C.M.Gerrits, et al. The role of data mining in pharmacovigilance. Expert Opin Drug Saf. 2005;4(5):929–948.• Describes application of data mining signals generated from voluntary surveillance systems
12. V.Garg, D.W.Raisch, J.M.McKoy, et al. Impact of United States Food and Drug Administration’s boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs. Expert Opin Drug Saf. 2013;12(3):299–307.
13. S.J.Evans, P.C.Waller, S.Davis. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483–486.
14. M.E.Mazda, J.R.Brosch, A.L.Wiens, et al. A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JCV testing. Int J Neurosci. 2013;123(5):353–357.
15. M.Tuccori, D.Focosi, C.Blandizzi, et al. Inclusion of rituximab in treatment protocols for non-Hodgkin’s lymphomas and risk for progressive multifocal leukoencephalopathy. Oncologist. 2010;15(11):1214–1219.
16. N.S.Vermeer, S.M.Straus, A.K.Mantel-Teeuwisse, et al. Drug-induced progressive multifocal leukoencephalopathy:Lessons learned from contrasting natalizumab and rituximab. Clin Pharmacol Ther. 2015;98(5):542–550.• Describes differences in PML occurrences between two therapies
17. C.McGuigan, M.Craner, J.Guadagno, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk:Recommendations from an expert group. J Neurol Neurosurg Psychiatry. 2016;87(2):117–125.•• Provides methodology for determing potential risk of natalizumab-associated PML among MS patients
18. K.R.Carson, S.D.Newsome, E.J.Kim, et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy:a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer. 2014;120(16):2464–2471.• An early summary of PML associated with rituximab using FAERS
19. C.L.Bennett, J.R.Nebeker, E.A.Lyons, et al. The Research on Adverse Drug Events and Reports (RADAR) project. JAMA. 2005;293(17):2131–2140.•• Describes a methodology for reporting rare serious adverse drug events and initial results
20. L.Isidoro, P.Pires, L.Rito, et al. Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab. BMJ Case Rep. 2014;2014.
21. J.Waggoner, T.Martinu, S.M.Palmer Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. J Heart Lung Transplant. 2009;28(4):395–398.
22. C.A.Fredericks, K.A.Kvam, J.Bear, et al. A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab. Lupus. 2014;23(7):711–713.
23. C.Leblanc-Trudeau, A.Masetto, C.Bocti. Progressive multifocal leukoencephalopathy associated with belimumab in a patient with systemic lupus erythematosus. J Rheumatol. 2015;42(3):551–552.
24. P.Jalan, A.Mahajan, V.Pandav, et al. Brentuximab associated progressive multifocal leukoencephalopathy. Clin Neurol Neurosurg. 2012;114(10):1335–1337.
25. N.D.Wagner-Johnston, N.L.Bartlett, A.Cashen, et al. Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Leuk Lymphoma. 2012;53(11):2283–2286.
26. C.Moreno, M.Montillo, P.Panayiotidis, et al. Ofatumumab in poor-prognosis chronic lymphocytic leukemia:a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. Haematologica. 2015;100(4):511–516.
27. É.Toussirot, M.Bereau. The risk of progressive multifocal leukoencephalopathy under biological agents used in the treatment of chronic inflammatory diseases. Inflamm Allergy Drug Targets. 2014;13(2):121–127.
28. A.Bharat, F.Xie, J.W.Baddley, et al. Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases. Arthritis Care Res (Hoboken). 2012;64(4):612–615.
29. E.S.Molloy, L.H.Calabrese. Progressive multifocal leukoencephalopathy:a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum. 2009;60(12):3761–3765.
30. J.García-Suárez, D.De Miguel, I.Krsnik, et al. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders:impact of novel therapies. Am J Hematol. 2005;80(4):271–281.
31. C.L.Bennett, S.D.Newsome, O.Sartor, et al. Reply to magnetic resonance imaging-based diagnosis of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma after therapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab. Cancer. 2014 15;120(24):4006–4007.
32. L.B.Norris, P.Georgantopoulos, G.A.Rao, et al. Association between rituximab use and progressive multifocal leukoencephalopathy among non-HIV, non-Hodgkin lymphoma Veteran’s Administration patients. American Society of Clinical Oncology Annual Meeting 2014 [cited 2016 Jan8]. Available from: http://meetinglibrary.asco.org/content/132159-144
33. J.R.Berger, A.J.Aksamit, D.B.Clifford, et al. PML diagnostic criteria:consensus statement from the AAN neuroinfectious disease section. Neurology. 2013;80(15):1430–1438.
34. T.Plavina, M.Subramanyam, G.Bloomgren, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014;76(6):802–812.
35. F.Serana, M.Chiarini, A.Sottini, et al. Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy. J Neuroimmunol. 2014;277(1–2):6–12.
36. D.Borie, J.M.Kremer. Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2015;45(2):163–166.
37. C.Piccinni, C.Sacripanti, E.Poluzzi, et al. Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents. Eur J Clin Pharmacol. 2010;66(2):199–206.
38. D.B.Clifford, A.De Luca, D.M.Simpson, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis:lessons from 28 cases. Lancet Neurol. 2010;9(4):438–446.• A summary of treatments of PML among MS patients.
39. W.Wenning, A.Haghikia, J.Laubenberger, et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med. 2009;361(11):1075–1080.
40. D.Pavlovic, A.C.Patera, F.Nyberg, et al. Progressive multifocal leukoencephalopathy:current treatment options and future perspectives. Ther Adv Neurol Disord. 2015;8(6):255–273.
41. I.L.Tan, J.C.McArthur, D.B.Clifford, et al. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology. 2011;13;77(11):1061–1067.
42. K.Tan, R.Roda, L.Ostrow, et al. PML-IRIS in patients with HIV infection:clinical manifestations and treatment with steroids. Neurology. 2009;72(17):1458–1464.
43. J.Travis, A.Varma, D.Du Plessis, et al. Immune reconstitution associated with progressive multifocal leukoencephalopathy in human immunodeficiency virus:a case discussion and review of the literature. Neurologist. 2008;14(5):321–326.
44. D.Przepiorka, K.A.Jaeckle, R.R.Birdwell, et al. Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2. Bone Marrow Transplant. 1997;20(11):983–987.
45. D.Re, S.Bamborschke, W.Feiden, et al. Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy. Bone Marrow Transplant. 1999;23(3):295–298.
46. L.Kunschner, T.F.Scott. Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2. Neurology. 2005;65(9):1510.
47. K.B.Alstadhaug, T.Croughs, S.Henriksen, et al. Treatment of progressive multifocal leukoencephalopathy with interleukin 7. JAMA Neurol. 2014;71(8):1030–1035.
48. M.Sospedra, S.Schippling, S.Yousef, et al. Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1. Clin Infect Dis. 2014;59(11):1588–1592.
49. A.Alvarez-Requejo, A.Carvajal, B.Bégaud, et al. Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol. 1998;54(6):483–488.
50. M.Bäckström, T.Mjörndal, R.Dahlqvist. Under-reporting of serious adverse drug reactions in Sweden. Pharmacoepidemiol Drug Saf. 2004;13(7):483–487.
51. I.R.Edwards. Pharmacovigilance. Br J Clin Pharmacol. 2012;73(6):979–982.
52. C.Pierfitte, B.Begaud, R.Lagnaoui, et al. Is reporting rate a good predictor of risks associated with drugs? Br J Clin Pharmacol. 1999;47(3):329–331.
53. C.A.Naranjo, N.H.Shear, K.L.Lanctôt. Advances in the diagnosis of adverse drug reactions. J Clin Pharmacol. 1992;32(10):897–904.